Research programme: apolipoprotein A-I stimulants - VIRxSYS

Drug Profile

Research programme: apolipoprotein A-I stimulants - VIRxSYS

Alternative Names: Lipid disorders gene therapy - VIRxSYS; Research programme - dyslipidemia gene therapy - VIRxSYS; SMaRT ApoA1; VRX1243

Latest Information Update: 17 Feb 2011

Price : $50

At a glance

  • Originator Intronn
  • Developer VIRxSYS Corporation
  • Class Gene therapies
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Dyslipidaemias

Most Recent Events

  • 17 Feb 2011 Preclinical development is ongoing in USA
  • 17 Jan 2008 VIRxSYS establishes CRADA with the National Heart, Lung, and Blood Institute (NHLBI) for the development of therapeutics in Atherosclerosis
  • 21 Sep 2007 Intronn has been acquired and merged into VIRxSYS Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top